Skip to main content
SpringerLink
Log in

Enforced expression of cytosolic 5′-nucleotidase I confers resistance to nucleoside analogues in vitro but systemic chemotherapy toxicity precludes in vivo selection

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose: Retroviral transfer of cDNA sequences that confer drug resistance can be used to protect against chemotherapy-induced hematopoietic toxicity and for the selective expansion of gene-modified cells. To successfully expand genetically engineered cells in vivo, an appropriate balance must be achieved between systemic toxicity induced by the selecting agent and the expansion of modified cells. Method: In this study, we investigate retroviral transfer of cytosolic 5′-nucleotidase I (cN-I) for protection and selection of gene-modified cells when treated with 2-chloro-2′-deoxyadenosine (2-CdA) and 5-fluorouracil (5-FU) alone and in combination. We also attempt to design a treatment strategy for the potential in vivo selection of cN-I-modified cells by administering 5-FU to mice prior to 2-CdA treatment. Results: Our results show that cN-I can be transferred by recombinant retroviruses, and that enforced expression of cN-I protects murine fibroblast and hematopoietic progenitor cells from the cytotoxic effects of 2-CdA and/or 5-FU. Furthermore, we show that the combined administration of 5-FU and 2-CdA potentiates hematopoietic stem cell toxicity. However, the treatment also results in severe myelosuppression. Conclusion: These results show that while cN-I provides both protective and selective benefits to gene-modified cells in vitro, selection requires a treatment strategy that is likely too toxic to consider cN-I as an in vivo selectable marker

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Allay JA, Dumenco LL, Koc ON, Liu L, Gerson SL (1995) Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells. Blood 85(11):3342–3351

    PubMed  CAS  Google Scholar 

  2. Allay JA, Galipeau J, Blakley RL, Sorrentino BP (1998) Retroviral vectors containing a variant dihydrofolate reductase gene for drug protection and in vivo selection of hematopoietic cells. Stem Cells 16(Suppl. 1):223–233

    PubMed  Google Scholar 

  3. Allay JA, Spencer HT, Wilkinson SL, Belt JA, Blakley RL, Sorrentino BP (1997) Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors. Blood 90(9):3546–3554

    PubMed  CAS  Google Scholar 

  4. Beausejour CM, Eliopoulos N, Momparler L, Le NL, Momparler RL (2001) Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene. Cancer Gene Ther 8(9):669–676

    Article  PubMed  CAS  Google Scholar 

  5. Blau CA, Neff T, Papayannopoulou T (1996) The hematological effects of folate analogs: implications for using the dihydrofolate reductase gene for in vivo selection. Hum Gene Ther 7(17):2069–2078

    Article  PubMed  CAS  Google Scholar 

  6. Bodine DM, McDonagh KT, Seidel NE, Nienhuis AW (1991) Survival and retrovirus infection of murine hematopoietic stem cells in vitro: effects of 5-FU and method of infection. Exp Hematol 19(3):206–212

    PubMed  CAS  Google Scholar 

  7. Bowman JE, Reese JS, Lingas KT, Gerson SL (2003) Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients. Mol Ther 8(1):42–50

    Article  PubMed  CAS  Google Scholar 

  8. Capiaux GM, Budak-Alpdogan T, Alpdogan O, Bornmann W, Takebe N, Banerjee D, Maley F, Bertino JR (2004) Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene. Cancer Gene Ther 11(12):767–773

    Article  PubMed  CAS  Google Scholar 

  9. Carson DA, Kaye J, Wasson DB (1981) The potential importance of soluble deoxynucleotidase activity in mediating deoxyadenosine toxicity in human lymphoblasts. J Immunol 126(1):348–352

    PubMed  CAS  Google Scholar 

  10. Chow KU, Boehrer S, Bojunga J, Stieler M, Rummel MJ, Fauth F, Schneider B, Martin H, Hoelzer D, Weidmann E, Mitrou PS (2002) Induction of apoptosis by cladribine (2-CdA), gemcitabine and other chemotherapeutic drugs on CD34+/CD38+ and CD34+/CD38- hematopoietic progenitor cells: selective effects of doxorubicin and 2-CdA with protection of immature cells. Leuk Lymphoma 43(2):377–384

    PubMed  CAS  Google Scholar 

  11. Eliopoulos N, Al-Khaldi A, Beausejour CM, Momparler RL, Momparler LF, Galipeau J (2002) Human cytidine deaminase as an ex vivo drug selectable marker in gene-modified primary bone marrow stromal cells. Gene Ther 9(7):452–462

    Article  PubMed  CAS  Google Scholar 

  12. Galmarini CM, Graham K, Thomas X, Calvo F, Rousselot P, El Jafaari A, Cros E, Mackey JR, Dumontet C (2001a) Expression of high Km 5′-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood 98(6):1922–1926

    Article  CAS  Google Scholar 

  13. Galmarini CM, Mackey JR, Dumontet C (2001b) Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15(6):875–890

    Article  CAS  Google Scholar 

  14. Gora-Tybor J, Robak T (1993) The influence of 2-chlorodeoxyadenosine alone and in combination with cyclophosphamide or methotrexate on normal hematopoiesis in mice. Acta Haematol Pol 24(3):281–287

    PubMed  CAS  Google Scholar 

  15. Greyz N, Saven A (2004) Cladribine: from the bench to the bedside—focus on hairy cell leukemia. Expert Rev Anticancer Ther 4(5):745–757

    Article  PubMed  CAS  Google Scholar 

  16. Guchelaar HJ, Vermes I, Koopmans RP, Reutelingsperger CP, Haanen C (1998) Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model. Cancer Chemother Pharmacol 42(1):77–83

    Article  PubMed  CAS  Google Scholar 

  17. Harrison DE, Lerner CP (1991) Most primitive hematopoietic stem cells are stimulated to cycle rapidly after treatment with 5-fluorouracil. Blood 78(5):1237–1240

    PubMed  CAS  Google Scholar 

  18. Hunsucker SA, Spychala J, Mitchell BS (2001) Human cytosolic 5′-nucleotidase I: characterization and role in nucleoside analog resistance. J Biol Chem 276(13):10498–10504

    Article  PubMed  CAS  Google Scholar 

  19. Johnson SA (2001) Nucleoside analogues in the treatment of haematological malignancies. Expert Opin Pharmacother 2(6):929–943

    Article  PubMed  CAS  Google Scholar 

  20. Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA (1993) Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 81(3):597–601

    PubMed  CAS  Google Scholar 

  21. Klopfer A, Hasenjager A, Belka C, Schulze-Osthoff K, Dorken B, Daniel PT (2004) Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway. Oncogene 23(58):9408–9418

    Article  PubMed  Google Scholar 

  22. Licht T, Goldenberg SK, Vieira WD, Gottesman MM, Pastan I (2000) Drug selection of MDR1-transduced hematopoietic cells ex vivo increases transgene expression and chemoresistance in reconstituted bone marrow in mice. Gene Ther 7(4):348–358

    Article  PubMed  CAS  Google Scholar 

  23. Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3(5):330–338

    Article  PubMed  CAS  Google Scholar 

  24. Lotfi K, Juliusson G, Albertioni F (2003) Pharmacological basis for cladribine resistance. Leuk Lymphoma 44(10):1705–1712

    Article  PubMed  CAS  Google Scholar 

  25. Magro PG, Russo AJ, Li WW, Banerjee D, Bertino JR (2004) p14ARF expression increases dihydrofolate reductase degradation and paradoxically results in resistance to folate antagonists in cells with nonfunctional p53. Cancer Res 64(12):4338–4345

    Article  PubMed  CAS  Google Scholar 

  26. Marzo I, Perez-Galan P, Giraldo P, Rubio-Felix D, Anel A, Naval J (2001) Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria. Biochem J 359(Pt 3):537–546

    Article  PubMed  CAS  Google Scholar 

  27. McMillin DW, Landazuri N, Gangadharan B, Hewes B, Archer DR, Spencer HT, Le Doux JM (2005) Highly efficient transduction of repopulating bone marrow cells using rapidly concentrated polymer-complexed retrovirus. Biochem Biophys Res Commun 330(3):768–775

    Article  PubMed  CAS  Google Scholar 

  28. Persons DA, Allay JA, Bonifacino A, Lu T, Agricola B, Metzger ME, Donahue RE, Dunbar CE, Sorrentino BP (2004) Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors. Blood 103(3):796–803

    Article  PubMed  CAS  Google Scholar 

  29. Randall TD, Weissman IL (1997) Phenotypic and functional changes induced at the clonal level in hematopoietic stem cells after 5-fluorouracil treatment. Blood 89(10):3596–3606

    PubMed  CAS  Google Scholar 

  30. Rots MG, Pieters R, Kaspers GJ, van Zantwijk CH, Noordhuis P, Mauritz R, Veerman AJ, Jansen G, Peters GJ (1999) Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay. Blood 93(3):1067–1074

    PubMed  CAS  Google Scholar 

  31. Sawai N, Persons DA, Zhou S, Lu T, Sorrentino BP (2003) Reduction in hematopoietic stem cell numbers with in vivo drug selection can be partially abrogated by HOXB4 gene expression. Mol Ther 8(3):376–384

    Article  PubMed  CAS  Google Scholar 

  32. Schiedlmeier B, Wermann K, Kuhlcke K, Eckert HG, Baum C, Fruehauf S, Zeller WJ (2000) Human multidrug resistance-1 gene transfer to long-term repopulating human mobilized peripheral blood progenitor cells. Bone Marrow Transplant 25(Suppl. 2):S118–124

    Article  PubMed  Google Scholar 

  33. Spencer HT, Sleep SE, Rehg JE, Blakley RL, Sorrentino BP (1996) A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood 87(6):2579–2587

    PubMed  CAS  Google Scholar 

  34. Zhao SC, Li MX, Banerjee D, Schweitzer BI, Mineishi S, Gilboa E, Bertino JR (1994) Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase. Cancer Gene Ther 1(1):27–33

    PubMed  CAS  Google Scholar 

  35. Zielske SP, Reese JS, Lingas KT, Donze JR, Gerson SL (2003) In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning. J Clin Invest 112(10):1561–1570

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Animal Resources, Emory University, 2015 Uppergate Drive, Room 420, Atlanta, GA, 30322, USA

    Tasha Gray

  2. Division of Hematology/Oncology and Bone Marrow Transplantation, Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Emory University School of Medicine, 2015 Uppergate Drive, Room 420, Atlanta, GA, 30322, USA

    Erin L. Morrey, Bagirath Gangadharan, David R. Archer & H. Trent Spencer

  3. Department of Chemistry, Physics, and Geology, Winthrop University, Rock Hill, SC, 29733, USA

    Takita F. Sumter

  4. Department of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27559, USA

    Jozef Spychala

Authors
  1. Tasha Gray
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erin L. Morrey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bagirath Gangadharan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takita F. Sumter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jozef Spychala
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David R. Archer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. Trent Spencer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Trent Spencer.

Additional information

Tasha Gray, Erin L. Morrey contributed equally to this work

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gray, T., Morrey, E.L., Gangadharan, B. et al. Enforced expression of cytosolic 5′-nucleotidase I confers resistance to nucleoside analogues in vitro but systemic chemotherapy toxicity precludes in vivo selection. Cancer Chemother Pharmacol 58, 117–128 (2006). https://doi.org/10.1007/s00280-005-0156-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-005-0156-7

Keywords

Search

Navigation